Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GNPAT | O15228 | 2/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27610443 | 0.84 | KDM4E (0.61) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL17623527 | 0.82 | KDM4E (0.48) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL17088566 | 0.82 | KDM4E (0.48) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL13301136 | 0.81 | ENPEP (0.34) | GNPATCA1CA2ANPEPENPEP | |
| SCHEMBL3019175 | 0.81 | SIRT6 (0.49) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL10070143 | 0.80 | KDM4E (0.50) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL14111193 | 0.79 | KDM4E (0.54) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL12231861 | 0.79 | SIRT6 (0.55) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Hydrazine SCHEMBL9545541 | 0.78 | SMN1; SMN2 (0.64) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL6403037 | 0.78 | SIRT6 (0.57) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2018-09-20 | — | — | US | claimed |
| WO-2006069366-A1 | METHODS OF PROTEIN PROFILING BY THIOLATION | INTEL CORPORATION (US) | 2006-06-29 | — | — | WO | claimed |
| US-20060134694-A1 | Methods of protein profiling by thiolation | INTEL CORPORATION (US) | 2006-06-22 | — | — | US | claimed |
| WO-1994003496-A1 | BIOMATERIALS AND BIOSENSORS CONTAINING IMMOBILIZED MODIFIED ANTIBODIES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1994-02-17 | — | — | WO | claimed |
| CN-119931076-B | Method for synthesizing metal organic framework material by aqueous phase one-pot method | JINAN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TALLAC THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260021091-A1 | PHARMACEUTICAL COMPOSITIONS | ViiV Healthcare UK (No.3) Limited (GB) | 2026-01-22 | — | — | US | disclosed |
| EP-4646595-A1 | PEPTIDE SEQUENCER | Oregon Health & Science University (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | Tallac Therapeutics, Inc. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250215467-A1 | L-THREONINE TRANSALDOLASES AND USES THEREOF | UNIVERSITY OF DELAWARE (US) | 2025-07-03 | — | — | US | disclosed |
| US-12343354-B2 | Injection containing p-boronophenylalanine | STELLA PHARMA CORPORATION (JP) | 2025-07-01 | — | — | US | disclosed |
| WO-1998004739-A2 | HOMOGENEOUS DIAGNOSTIC ASSAY METHOD UTILIZING SIMULTANEOUS TARGET AND SIGNAL AMPLIFICATION | NAVIX, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| US-5635487-A | DRUG DELIVERY | BUDKER, TATYANA | 1997-06-03 | — | — | US | disclosed |
| WO-1997001330-A1 | NOVEL ADJUVANT COMPOSITIONS AND VACCINE FORMULATIONS COMPRISING SAME | RESEARCH TRIANGLE PHARMACEUTICALS (US) | 1997-01-16 | — | — | WO | disclosed |
| WO-1994003496-A1 | BIOMATERIALS AND BIOSENSORS CONTAINING IMMOBILIZED MODIFIED ANTIBODIES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1994-02-17 | — | — | WO | disclosed |
| US-5276140-A | Hydrazide, semicarbazide or thiosemicarbizide agents for linking aldehydes or sulfhydryl groups | CETUS ONCOLOGY CORPORATION (US) | 1994-01-04 | — | — | US | disclosed |
| US-5034514-A | Agents for crosslinking aldehyde groups to sulfhydryl groups in immunoglobulins | CETUS CORPORATION (US) | 1991-07-23 | — | — | US | disclosed |
| US-4797491-A | SPACERS; BIOCHEMICAL | CETUS CORPORATION (US) | 1989-01-10 | — | — | US | disclosed |
| EP-0240200-A2 | Cross-linking agents, their use and preparation | CETUS CORPORATION (US) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021091-A1 | PHARMACEUTICAL COMPOSITIONS | SMCHD1, SAMM50, PRPF40A | KDM4E 1594/4885MAPT 351/4885THRB 4816/4885 |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | KDM4E 3872/4885MAPT 4327/4885THRB 4361/4885 |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | UNG, DUT, TYMP | KDM4E 3462/4885MAPT 847/4885THRB 2132/4885 |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | KDM4E 300/4885MAPT 1931/4885THRB 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.